HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“tumor hypoxia generates macrophages that can suppress T cell responses. This suppressive phenotype is mediated by hypoxic induction of arginase 1 and nitric oxide synthase, both that restrict T cell activation. Strikingly, induction of this hypoxic pathway in macrophages is required for optimal tumor growth [84, 85].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, tumor hypoxia and/or HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010), regulatory T-cells (Clambey et al., 2012), and tumor-associated macrophages (Doedens et al., 2010;Imtiyaz et al., 2010) with immunosuppressive functions.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Corzo et al., 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [56]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“Extensive studies in recent years suggested several mechanisms of MDSC-mediated immune suppression that involve arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 2008) and cysteine (Srivastava et al., 2010) metabolism, expression of some surface molecules (Pan et al., 2010), up-regulation…”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationAlmand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationMovahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Cited by
Items 101–200 of 1,000
The CCL20-CCR6 Axis in Cancer Progression
Kadomoto, S., Izumi, K., & Mizokami, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155186 · Cited by 267
Li, L., Wang, L., Li, J., Fan, Z., Yang, L., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Pre-metastatic niche: formation, characteristics and therapeutic implication
Wang, Y., Jia, J., Wang, F., Fang, Y., Yang, Y., Zhou, Q., Yuan, W., Gu, X., Hu, J., & Yang, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01937-7 · Cited by 246
Exosome-orchestrated hypoxic tumor microenvironment
Meng, W., Hao, Y., He, C., Li, L., & Zhu, G. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0982-6 · Cited by 251
Krempski, J., Karyampudi, L., Behrens, M. D., Erskine, C. L., Hartmann, L., Dong, H., Goode, E. L., Kalli, K. R., & Knutson, K. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100274 · Cited by 251
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
Filipazzi, P., Huber, V., & Rivoltini, L. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1161-9 · Cited by 243
Daurkin, I., Eruslanov, E., Stoffs, T., Perrin, G. Q., Algood, C., Gilbert, S. M., Rosser, C. J., Su, L.-M., Vieweg, J., & Kusmartsev, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1261 · Cited by 235
McNamee, E. N., Korns Johnson, D., Homann, D., & Clambey, E. T. (2013) · Immunologic Research · doi:10.1007/s12026-012-8349-8 · Cited by 234
On the origin of myeloid-derived suppressor cells
Millrud, C. R., Bergenfelz, C., & Leandersson, K. (2017) · Oncotarget · doi:10.18632/oncotarget.12278 · Cited by 230
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 230
Colonic macrophage polarization in homeostasis, inflammation, and cancer
Isidro, R. A., & Appleyard, C. B. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00123.2016 · Cited by 229
Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients
Wu, W.-C., Sun, H.-W., Chen, H.-T., Liang, J., Yu, X.-J., Wu, C., Wang, Z., & Zheng, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320753111 · Cited by 227
Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., & Sasaki, H. (2020) · Medical Oncology · doi:10.1007/s12032-019-1329-2 · Cited by 226
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 222
The role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
Phenotype, development, and biological function of myeloid-derived suppressor cells
Zhao, Y., Wu, T., Shao, S., Shi, B., & Zhao, Y. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1004983 · Cited by 220
Thiele Orberg, E., Fan, H., Tam, A. J., Dejea, C. M., Destefano Shields, C. E., Wu, S., Chung, L., Finard, B. B., Wu, X., Fathi, P., et al. (2017) · Mucosal Immunology · doi:10.1038/mi.2016.53 · Cited by 219
Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma
Ma, Q., Long, W., Xing, C., Chu, J., Luo, M., Wang, H. Y., Liu, Q., & Wang, R.-F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02924 · Cited by 219
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Gupta, S., Roy, A., & Dwarakanath, B. S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00068 · Cited by 218
Irradiation Promotes an M2 Macrophage Phenotype in Tumor Hypoxia
Chiang, C.-S., Fu, S. Y., Wang, S.-C., Yu, C.-F., Chen, F.-H., Lin, C.-M., & Hong, J.-H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00089 · Cited by 217
Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma
Kirschenbaum, D., Xie, K., Ingelfinger, F., Katzenelenbogen, Y., Abadie, K., Look, T., Sheban, F., Phan, T. S., Li, B., Zwicky, P., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.032 · Cited by 211
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Dysthe, M., & Parihar, R. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-35723-8_8 · Cited by 210
Lactate dehydrogenase: a marker of diminished antitumor immunity
Van Wilpe, S., Koornstra, R., Den Brok, M., De Groot, J. W., Blank, C., De Vries, J., Gerritsen, W., & Mehra, N. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1731942 · Cited by 208
Myeloid‐derived suppressor cells in cancer: recent progress and prospects
Khaled, Y. S., Ammori, B. J., & Elkord, E. (2013) · Immunology & Cell Biology · doi:10.1038/icb.2013.29 · Cited by 209
Lechner, M. G., Megiel, C., Russell, S. M., Bingham, B., Arger, N., Woo, T., & Epstein, A. L. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-90 · Cited by 209
Yang, Y., Liu, X., Ma, W., Xu, Q., Chen, G., Wang, Y., Xiao, H., Li, N., Liang, X.-J., Yu, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120456 · Cited by 209
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 207
Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H. R., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.004 · Cited by 203
Lung Tumor Cell-Derived Exosomes Promote M2 Macrophage Polarization
Pritchard, A., Tousif, S., Wang, Y., Hough, K., Khan, S., Strenkowski, J., Chacko, B. K., Darley-Usmar, V. M., & Deshane, J. S. (2020) · Cells · doi:10.3390/cells9051303 · Cited by 204
Almendros, I., Wang, Y., Becker, L., Lennon, F. E., Zheng, J., Coats, B. R., Schoenfelt, K. S., Carreras, A., Hakim, F., Zhang, S. X., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1830oc · Cited by 201
Laoui, D., Van Overmeire, E., De Baetselier, P., Van Ginderachter, J. A., & Raes, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00489 · Cited by 200
Abou Khouzam, R., Brodaczewska, K., Filipiak, A., Zeinelabdin, N. A., Buart, S., Szczylik, C., Kieda, C., & Chouaib, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613114 · Cited by 198
Hypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
“MDSCs cultured with the hypoxia mimetic desferroxamine (DFO) robustly suppress T cell proliferation and loss of HIF-1α decreases MDSC-mediated T cell suppression (98).”
BackgroundLiu, G., Bi, Y., Shen, B., Yang, H., Zhang, Y., Wang, X., Liu, H., Lu, Y., Liao, J., Chen, X., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2584 · Cited by 199
Baginska, J., Viry, E., Paggetti, J., Medves, S., Berchem, G., Moussay, E., & Janji, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00490 · Cited by 198
Li, Y., Patel, S. P., Roszik, J., & Qin, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 195
The link between immunity, autoimmunity and endometriosis: a literature update
Zhang, T., De Carolis, C., Man, G. C. W., & Wang, C. C. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.03.017 · Cited by 196
Najjar, Y. G., Rayman, P., Jia, X., Pavicic, P. G., Rini, B. I., Tannenbaum, C., Ko, J., Haywood, S., Cohen, P., Hamilton, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1823 · Cited by 194
Tacke, R. S., Lee, H.-C., Goh, C., Courtney, J., Polyak, S. J., Rosen, H. R., & Hahn, Y. S. (2012) · Hepatology · doi:10.1002/hep.24700 · Cited by 195
Stienstra, R., Netea-Maier, R. T., Riksen, N. P., Joosten, L. A. B., & Netea, M. G. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.001 · Cited by 194
Barriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
Biswas, S., Mandal, G., Roy Chowdhury, S., Purohit, S., Payne, K. K., Anadon, C., Gupta, A., Swanson, P., Yu, X., Conejo-Garcia, J. R., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900692 · Cited by 194
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
NK cells and solid tumors: therapeutic potential and persisting obstacles
Tong, L., Jiménez-Cortegana, C., Tay, A. H. M., Wickström, S., Galluzzi, L., & Lundqvist, A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01672-z · Cited by 189
Vitamin C and immune cell function in inflammation and cancer
Ang, A., Pullar, J. M., Currie, M. J., & Vissers, M. C. M. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180169 · Cited by 191
Sawant, A., Hensel, J. A., Chanda, D., Harris, B. A., Siegal, G. P., Maheshwari, A., & Ponnazhagan, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101855 · Cited by 191
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
The Role of Tumor Microenvironment Cells in Colorectal Cancer (CRC) Cachexia
Kasprzak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041565 · Cited by 189
Donlon, N. E., Power, R., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 189
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
Halaby, M. J., Hezaveh, K., Lamorte, S., Ciudad, M. T., Kloetgen, A., MacLeod, B. L., Guo, M., Chakravarthy, A., Medina, T. D. S., Ugel, S., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aax8189 · Cited by 186
DC-SIGN+ Macrophages Control the Induction of Transplantation Tolerance
Conde, P., Rodriguez, M., van der Touw, W., Jimenez, A., Burns, M., Miller, J., Brahmachary, M., Chen, H.-M., Boros, P., Rausell-Palamos, F., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.009 · Cited by 187
Nicolini, A., & Ferrari, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353787 · Cited by 182
Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.010 · Cited by 185
Szebeni, G. J., Vizler, C., Kitajka, K., & Puskas, L. G. (2017) · Mediators of Inflammation · doi:10.1155/2017/9294018 · Cited by 184
The Good and the Bad: Monocytes’ and Macrophages’ Diverse Functions in Inflammation
Austermann, J., Roth, J., & Barczyk-Kahlert, K. (2022) · Cells · doi:10.3390/cells11121979 · Cited by 183
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W.-H., & Wong, C. C.-L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 183
The Metabolic Mechanisms of Breast Cancer Metastasis
Wang, L., Zhang, S., & Wang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.602416 · Cited by 182
Sawant, A., Deshane, J., Jules, J., Lee, C. M., Harris, B. A., Feng, X., & Ponnazhagan, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2202 · Cited by 182
IL-21 and T follicular helper cells
Spolski, R., & Leonard, W. J. (2010) · International Immunology · doi:10.1093/intimm/dxp112 · Cited by 183
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00021 · Cited by 180
Van Overmeire, E., Laoui, D., Keirsse, J., Van Ginderachter, J. A., & Sarukhan, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00127 · Cited by 180
Hypoxia-induced epithelial to mesenchymal transition in cancer
Hapke, R. Y., & Haake, S. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.012 · Cited by 178
Hypoxia and HIF Signaling: One Axis with Divergent Effects
Corrado, C., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165611 · Cited by 179
Tumor immune microenvironment in head and neck cancers
Chen, S. M. Y., Krinsky, A. L., Woolaver, R. A., Wang, X., Chen, Z., & Wang, J. H. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23162 · Cited by 179
Kwak, T., Wang, F., Deng, H., Condamine, T., Kumar, V., Perego, M., Kossenkov, A., Montaner, L. J., Xu, X., Xu, W., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108571 · Cited by 178
Self-citationOn the armament and appearances of human myeloid-derived suppressor cells
Poschke, I., & Kiessling, R. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.06.003 · Cited by 177
Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells
Nagaraj, S., Youn, J.-I., & Gabrilovich, D. I. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300654 · Cited by 177
Self-citationMyeloid-Derived Suppressor Cells: A Propitious Road to Clinic
Grover, A., Sanseviero, E., Timosenko, E., & Gabrilovich, D. I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0764 · Cited by 175
Self-citationMyeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications
Diaz-Montero, C. M., Finke, J., & Montero, A. J. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.003 · Cited by 172
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 172
Tumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities
Beckers, C., Pruschy, M., & Vetrugno, I. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.006 · Cited by 167
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
Liu, S., Wang, W., Hu, S., Jia, B., Tuo, B., Sun, H., Wang, Q., Liu, Y., & Sun, Z. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06211-2 · Cited by 164
Camouflage and sabotage: tumor escape from the immune system
Poschke, I., Mougiakakos, D., & Kiessling, R. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1012-8 · Cited by 169
Pawlowska, E., Szczepanska, J., & Blasiak, J. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7286737 · Cited by 169
Zhou, J., Wu, J., Chen, X., Fortenbery, N., Eksioglu, E., Kodumudi, K. N., PK, E.-B., Dong, J., Djeu, J. Y., & Wei, S. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.007 · Cited by 167
Complexity and challenges in defining myeloid-derived suppressor cells
Damuzzo, V., Pinton, L., Desantis, G., Solito, S., Marigo, I., Bronte, V., & Mandruzzato, S. (2015) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21206 · Cited by 165
Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.020 · Cited by 164
Zheng, Y., Tian, X., Wang, T., Xia, X., Cao, F., Tian, J., Xu, P., Ma, J., Xu, H., & Wang, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0978-2 · Cited by 161
Myeloid cell heterogeneity in cancer: not a single cell alike
Kiss, M., Van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.008 · Cited by 159
Miret, J. J., Kirschmeier, P. T., Koyama, S., Zhu, M., Li, Y. Y., Naito, Y., Wu, M., Malladi, V. S., Huang, W., Walker, W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0504-5 · Cited by 170
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. A. (2020) · Molecules · doi:10.3390/molecules25204831 · Cited by 159
Protumor and antitumor functions of neutrophil granulocytes
Brandau, S., Dumitru, C. A., & Lang, S. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0344-6 · Cited by 158
Myeloid cells in hepatocellular carcinoma
Wan, S., Kuo, N., Kryczek, I., Zou, W., & Welling, T. H. (2015) · Hepatology · doi:10.1002/hep.27867 · Cited by 158
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S.-I. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 157
Köstlin, N., Kugel, H., Spring, B., Leiber, A., Marmé, A., Henes, M., Rieber, N. P., Hartl, D., Poets, C. F., & Gille, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201344200 · Cited by 157
SIRT1 and HIF1α signaling in metabolism and immune responses
Yu, Q., Lin, D., Li, Y., & Liu, G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.035 · Cited by 169
Oh, K., Lee, O.-Y., Shon, S. Y., Nam, O., Ryu, P. M., Seo, M. W., & Lee, D.-S. (2013) · Breast Cancer Research · doi:10.1186/bcr3473 · Cited by 156
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03048-x · Cited by 154
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis
Méndez-Huergo, S. P., Blidner, A. G., & Rabinovich, G. A. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.12.003 · Cited by 152
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 152
Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2013) · Neoplasia · doi:10.1593/neo.131748 · Cited by 152
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 152
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
Immune Response Regulation in the Tumor Microenvironment by Hypoxia
Labiano, S., Palazón, A., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.009 · Cited by 168
Kitamura, T., Doughty-Shenton, D., Cassetta, L., Fragkogianni, S., Brownlie, D., Kato, Y., Carragher, N., & Pollard, J. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.02004 · Cited by 150
Santoni, M., Massari, F., Amantini, C., Nabissi, M., Maines, F., Burattini, L., Berardi, R., Santoni, G., Montironi, R., Tortora, G., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1487-6 · Cited by 161
Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted
Tilstra, J. S., Avery, L., Menk, A. V., Gordon, R. A., Smita, S., Kane, L. P., Chikina, M., Delgoffe, G. M., & Shlomchik, M. J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120859 · Cited by 149
Metadata
- Authors
- Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-09-27
- Volume
- 207
- Issue
- 11
- Pages
- 2439-2453
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2964584
- OpenAlex
- W2109424201
- Semantic Scholar
- 77cf3cf3976e026979d2b7acf9b04119740a45f1
- Cited by
- 1,173
- References
- 56
- Citations by year
- 2026: 69 · 2025: 73 · 2024: 69 · 2023: 92 · 2022: 80 · 2021: 109 · 2020: 93 · 2019: 62 · 2018: 83 · 2017: 62 · 2016: 69 · 2015: 51 · 2014: 70 · 2013: 76 · 2012: 61
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute (CA84488, R01CA084488, R01CA103921, R01CA136828, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- myeloid-derived suppressor cells, HIF-1α, tumor microenvironment, hypoxia, tumor-associated macrophages, T cell suppression, arginase-1, inducible nitric oxide synthase, NADPH oxidase, reactive oxygen species, MDSC differentiation, immunosuppression
- MeSH terms
- Aged, Animals, Antigens, Neoplasm, Arginase, Cell Differentiation, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Middle Aged, Neoplasms, Cell Hypoxia, CD8-Positive T-Lymphocytes, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.